Highly aligned container-closure solutions for sterile injectables

Schott Kaisha and Vanrx Pharmasystems offer pre-validated pharma packaging

Highly aligned container-closure solutions for sterile injectables from Schott Kaisha and Vanrx Pharmasystems. Photo: Schott Kaisha

Schott Kaisha and Vanrx Pharmasystems are announcing compatibility between Schott Kaisha’s ready-to-use nested syringes, cartridges and stoppers, and Vanrx’s Aseptic Filling Workcells.

The two companies have worked together to confirm these containers and closures as product sets as part of the Matrix Alliance, an industry initiative of leading packaging and component suppliers which aims to providing pre-validated container-closure solutions to work on Vanrx’s robotic aseptic filling machines. The Alliance was created because next-generation drugs require highly aligned manufacturing processes and packaging solutions.

These product sets are fully commercially available and ready-to-use, with closure integrity performance results available from Schott Kaisha and Vanrx. Using these product sets, pharmaceutical companies have the assurance that the combination will function as a high-performance primary packaging system for sterile injectables. Additionally, all elements of the set have been proven for compatibility and machinability with Vanrx aseptic filling systems.

Companies can move drug products to market faster, by establishing flexible manufacturing operations using pre-sterilized, nested ready-to-use containers and closures in combination with Vanrx’s robotic aseptic filling systems. As of today, product set combinations are available in Schott Kaisha 1 mL long syringes with Schott Kaisha nested syringe stoppers in both 100 and 160 unit per nest configurations, and Schott Kaisha 3 mL cartridges with Schott Kaisha nested cartridge stoppers in a 100 unit per nest configuration. These products are certified to work with Vanrx’s SA25 Aseptic Filling Workcell.

Rishad Dadachanji, Schott Kaisha’s director said, “As ready-to-use solutions gain traction in the market, we are determined to create a large portfolio consisting of all standard sizes, commercially available to our customers. Apart from being able to offer only the packaging, Vanrx and Schott Kaisha have taken the initiative to have our components validated for compatibility and machinability with the Vanrx system. This pre-validated combination of a single machine and broad product portfolio allows us to provide tested and reliable solutions to our common customers, enabling them with the flexibility to fill multiple sizes and a variety of products with ease.”

Vanrx’s vice president of marketing, Greg Speakman said, “Vanrx and Schott Kaisha have seen how pharmaceutical companies are shifting toward building flexible manufacturing operations. Schott Kaisha and Vanrx are helping bring new products to market faster, benefiting the patient and our customers’ ability to respond to uncertain market conditions.”

Schott Kaisha is a leading manufacturer of tubular glass primary packaging in India having completed 25 years in this business. Schott and Kaisha established a 50:50 joint venture for primary packaging activities in India in 2008. With 2600 employees and 2.5 billion pieces per annum, Schott Kaisha produces ampoules, vials, glass refilled syringes and cartridges. Vanrx Pharmasystems makes technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges.

Packaging South Asia — resilient, growing and impactful — daily, monthly — always responsive

The multi-channel B2B in print and digital 17-year-old platform matches the industry’s growth trajectory. The Indian, South Asian, Southeast Asian, and Middle East packaging industries are looking beyond the resilience of the past three years. They are resuming capacity expansion and diversification, with high technology and automation in new plants and projects.

As we present our 2024 publishing plan, India’s real GDP growth for the financial year ending 31 March 2024 will exceed 6%. The packaging industry growth will match the GDP growth in volume terms and surpass it by at least 3% in terms of nominal growth allowing for price inflation in energy, raw materials, consumables, and capital equipment.

The capacity for flexible film manufacturing in India increased by 45% over the past four years. With orders in place, we expect another 20% capacity addition in 2024 and 2025. Capacities in monocartons, corrugation, aseptic liquid packaging, and labels are growing similarly. As the consumption story returns over the next six months, we expect demand to return and exceed the growth trajectory of previous years. The numbers are positive for most of the economies in the region – and as shown by our analytics, our platform increasingly reaches and influences these.

For responsible and sustainable packaging, with its attendant regulations and compliances, there is significant headroom to grow in India and the region. Our coverage includes the entire packaging supply chain – from concept to shelf and to waste collection, sorting, and recycling.

We target brand owners, product managers, raw material suppliers, packaging designers and converters, and recyclers. This is a large and complex canvas – the only thing that can work is your agile thinking and innovation together with our continuous learning and persistence.

The coming year looks to be an up year in this region, and this is the right time to plan your participation and marketing communication – in our rich and highly targeted business platform with human resources on the ground. Share your thoughts and plans to inspire and mobilize our editorial and advertising teams!

For editorial info@ippgroup.in — for advertisement ads1@ippgroup.in and for subscriptions subscription@ippgroup.in

– Naresh Khanna (25 October 2023)

Subscribe Now
unnamed 1


Subscribe to our Newsletter


Please enter your comment!
Please enter your name here